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Abstract
Background: Syndemics of illicit drug use and HIV remain as significant public health issues around the world.
There has been increasing concern regarding the rapidly growing market of new psychoactive substances,
particularly in Asia. In response, the Japanese government has increasingly banned such substances in recent years.
We sought to identify the prevalence and correlates of use of quasi-legal psychoactive substances among people
living with HIV/AIDS (PLHIV) in Japan.
Methods: Data were derived from a nationwide survey of PLHIV conducted at nine leading HIV/AIDS care hospitals
between July and December 2013. The prevalence and correlates of the use of quasi-legal psychoactive substances
(e.g., synthetic cannabinoids, cathinone derivatives, etc. that had not been prohibited from using at the time of
survey) among male participants were examined using multivariate survey logistic regression.
Results: Among 963 study participants, the majority (95.3%) were male. The most commonly used drug among
men was quasi-legal psychoactive substances (55.3% ever and 12.8% in the previous year). In multivariate analysis,
the lifetime use of tryptamine-type derivatives (i.e., 5-MeO-DIPT or N,N-diisopropyl-5-methoxytryptamine) (adjusted
odds ratio [AOR]: 2.42; 95% confidence interval [CI]: 1.36–4.28) and methamphetamine/amphetamine (AOR: 3.59;
95% CI: 2.13–6.04) were independently associated with recent quasi-legal psychoactive substance use.
Conclusions: In our sample of male PLHIV in Japan, quasi-legal psychoactive substances were the most commonly
used drugs. Individuals who had ever used tryptamine-type derivatives or methamphetamine/amphetamine were
more likely to report recent quasi-legal psychoactive substance use, suggesting a potential shift in drug use patterns
from regulated to unregulated substances among this population. These findings indicate a need for further research
to examine implications for HIV care.
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Background
Many countries in the world are contending with syn-
demics of illicit drug use and HIV/AIDS [1, 2]. In Asia, un-
safe injection use of opioids has traditionally been a key
driver of HIV epidemics [2]. However, a growing body of
research indicates that non-injection use of amphetamine-
type stimulants is also common, and associated with an
elevated HIV risk [2–4]. Specifically, methamphetamine
use has been shown to be highly prevalent, particularly
among men who have sex with men (MSM), increase HIV
seroconversion due to the associated risky sexual behav-
iour, and compromise HIV treatment outcomes [5–7].
However, little is known about the extent and patterns of
use of other synthetic drugs in this context. This is con-
cerning because the Asia-Pacific region has recently expe-
rienced explosive increases in the availability of a variety of
quasi-legal, mostly synthetic psychoactive substances [8].
These substances are designed to mimic the pharmaco-
logical effects of regulated substances including metham-
phetamine [8].
In Japan, the prevalence of illicit drug use in the general
population has historically been low at <3% (lifetime use)
[9]. The prevalence of HIV infection has also been low at
<0.1% among the general population over the past three
decades [10]. However, as in other parts of Asia, the bur-
den of HIV is disproportionately concentrated among
MSM [10]. It has been estimated that MSM accounted for
over half of the recorded HIV diagnoses [11]. Previous
studies reported a very high prevalence (40%) of illicit
drug use among HIV-positive MSM in one hospital in
Tokyo [12]. Illicit drug use was identified as an independ-
ent predictor of loss to follow-up for HIV care and hepa-
titis C virus infection in this setting [13, 14]. However,
these studies did not fully differentiate the use of trad-
itional illicit drugs (e.g., methamphetamine, heroin) and
other quasi-legal psychoactive substances.
In response to the explosive spread of quasi-legal syn-
thetic psychoactive substances [15], the Japanese govern-
ment has made a series of important changes to the
drug control legislation over the past decade. Through
the 2006 amendment of the Pharmaceutical Affairs Law,
quasi-legal synthetic drugs that were deemed to have the
potential to cause health-related harms were newly clas-
sified as “Designated Substances” [15]. The supply of
these substances for non-medical purposes was prohib-
ited [15]. By March 2013, 106 substances, including
synthetic cannabinoids, tryptamine-type derivatives and
phenethylamine derivatives, were listed as Designated
Substances [15, 16]. Since 2013, generic scheduling for
certain types of synthetic cannabinoids and cathinone
derivatives has also been introduced [16].
Despite the tighter control of supply, the possession and
consumption of Designated Substances have remained
largely unregulated. By March 2013, only 13 of the 106
Designated Substances, including mephedrone and
tryptamine-type derivatives (e.g., 5-MeO-DIPT and Foxy
[N,N-diisopropyl-5-methoxytryptamine]), have been cate-
gorized as “Narcotics” under the Narcotics and Psychotro-
pics Control Law and thereby have been prohibited from
possessing and consuming [16]. As such, many Designated
Substances have continued to be sold as herbal products,
aroma products and bath salts, even in vending machines
on the street.
While drug use patterns could be affected by these
legislation changes, there is a paucity of epidemiologic
data regarding the use of quasi-legal psychoactive sub-
stances (i.e., substances that have not been prohibited
from possessing or consuming under the Narcotics and
Psychotropics Control Law) in Japan [9]. Given the
previous studies suggesting that illicit drug use could
compromise HIV care and increase adverse health out-
comes among HIV-positive MSM in this setting [13, 14],
we sought to identify the prevalence and correlates of
quasi-legal psychoactive substance use among a large na-
tionwide sample of people living with HIV/AIDS (PLHIV)
in Japan.
Methods
Study design
Data for this study were derived from a nationwide cross-
sectional survey of PLHIV conducted at nine leading HIV/
AIDS referral hospitals in Japan between July and Decem-
ber 2013. In brief, beginning in 2003, this is a quinquennial
survey that aims to investigate the health and lifestyles
among PLHIV in Japan. The nine hospitals included in the
survey represent tertiary care hospitals and collectively
cover the eight major geographical regions in Japan. In each
hospital, HIV/AIDS medical professionals were asked to re-
cruit their patients living with HIV/AIDS in a serial manner
as patients visit their hospitals. They explained the study
objectives and procedures to potential participants, and ob-
tained informed consent from them. The recruitment was
continued until approximately 40% of their patients pro-
vided informed consent. While we did not count the num-
ber of patients who refused to participate in the survey,
informal reports from hospitals indicated that such cases
were rare. Consented patients were asked to self-complete
an anonymous questionnaire and return it to an independ-
ent researcher using a self-addressed, stamped envelope
provided with the questionnaire. The questionnaire elicited
a range of information, including socio-demographic char-
acteristics, HIV-related clinical histories, general health sta-
tus, and substance use histories. All consented individuals
received a 500 Japanese Yen (approximately US$5.00) gift
certificate. The study was approved by the research ethics
boards at the Saitama Prefectural University as well as each
participating hospital.
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Participants and measures
In total, 1,100 (61.6%) of 1,786 consented individuals
completed and returned the questionnaire, including 51
(4.7%) females. For a gender-based descriptive analysis
of drug use patterns, the sample was restricted to 963
(87.5%) individuals (918 males and 45 females) who had
complete data. For an analysis examining correlates of
past year quasi-legal psychoactive substance use among
men, the sample was further restricted to 895 male par-
ticipants with complete data.
For the present analysis, the primary outcome of inter-
est was reporting quasi-legal psychoactive substance use
in the previous year, defined as answering “Yes” to a
question: “In the past year, have you used quasi-legal
drugs in the form of herbal products, aroma liquid, pow-
der, oil, bath salts, or amyl nitrites including ‘rush’ and
‘poppers’?” As such, quasi-legal psychoactive substances
encompassed a range of substances that had been largely
regulated as Designated Substances but had not been
prohibited from possessing or consuming under the
Narcotics and Psychotropics Control Law by December
2013. Specifically, these substances would include syn-
thetic cannabinoids, synthetic cathinones, phenethyla-
mine and thiophene derivatives, and amyl nitrites (e.g.,
rush, poppers). The term “quasi-legal drugs” was used
because it commonly referred to the aforementioned set
of quasi-legal psychoactive substances of our interest in
Japan, and also because people usually do not know the
exact substance contained in the product.
Then, we selected a range of explanatory variables that
we hypothesized were potentially associated with the out-
come. Socio-demographic characteristics included: age;
education (< secondary education vs. ≥ secondary educa-
tion); currently living alone (yes vs. no) and annual income
(<1 million, 1–2.99 million, 3–4.99 million vs. ≥ 5 million
Yen). HIV-related measures included: antiretroviral therapy
(ART) use (currently on ART vs. never on ART); ever had
AIDS (yes vs. no); perceived route of HIV exposure (male-
to-male sexual behaviour vs. other; as a proxy measure for
MSM); and engagement in HIV-related peer support
groups in the previous year (yes vs. no). Psychological dis-
tress was measured using the Kessler psychological distress
scale (K6) [17]. This variable was dichotomized into a score
of ≥ 13 vs. a score of < 13, using the recommended cut-off
score to screen serious mental illness [17]. Histories of Illicit
drug use included: ever used tryptamine-type derivatives
(i.e., 5-MeO-DIPT or Foxy [N,N-diisopropyl-5-methoxy-
tryptamine]), ever used cannabis, ever used methampheta-
mine/amphetamine, ever used MDMA, and ever used
heroin/cocaine (all yes vs. no).
Statistical analyses
First, socio-demographic and HV-related clinical charac-
teristics were compared between males and females,
using the Wilcoxon Rank Sum Test (for continuous
variables) and the Pearson’s Chi-squared test (for cat-
egorical variables). Since the prevalence of drug use
was extremely low among women (11.1% ever and 0%
in the previous year), descriptive statistics were used
to compare drug use patterns between males and
females.
For bivariate and multivariate analyses of factors pre-
dicting past year quasi-legal psychoactive substance use
among male participants, we used the survey logistic re-
gression in the SAS software to account for possible clus-
tering effects at the hospital level. A multivariate model
was fit using an a priori-defined statistical protocol
whereby all variables that were significantly associated
with past year quasi-legal psychoactive substance use at
the p < 0.05 level in the bivariate logistic regression ana-
lyses. In a sub-analysis, we examined the proportion of
those who had never used any illicit drugs (i.e.,
tryptamine-type derivatives, cannabis, methamphetamine/
amphetamine, MDMA, heroin or cocaine) among male
participants who used quasi-legal psychoactive substance
in the previous year. We also examined the propor-
tion of those who used drugs for sexual activities in
the previous year among the same aforementioned
sub-sample. All p-values were two-sided. All statistical
analyses were performed using SAS software version
9.3 (SAS, Cary, NC).
Results
In total, 963 participants were eligible for the present
study, including 45 (4.7%) females. Table 1 shows sample
characteristics and drug use patterns, stratified by gen-
der. As shown, the median age of the entire sample was
42 (interquartile range: 37–50) years. There was no sig-
nificant gender-based difference in age. While female
participants were more likely than males to be diagnosed
with HIV before 2005, the majority of both males and fe-
males reported currently receiving ART. Annual income
was significantly lower among women, compared to men.
Among men, more than half reported a history of illicit
drug use (including quasi-legal psychoactive substances),
while only a handful of women did so. Among men, the
most commonly used drug was quasi-legal psychoactive
substances, followed by 5-MeO-DPT/Foxy and metham-
phetamine/amphetamine. Of note, the use of 5-MeO-
DPT/Foxy in the previous year substantially dropped to
0.4%. Among women, the most commonly used drug was
cannabis, followed by quasi-legal psychoactive substances
and methamphetamine/amphetamine.
Table 2 shows the results of bivariate analyses of fac-
tors predicting past year quasi-legal psychoactive sub-
stance use among male participants. As shown, factors
significantly associated with the outcome included: age;
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currently living alone; male-to-male sexual behaviour as
a perceived route of HIV exposure; and all illicit drug
use histories considered.
Table 3 presents the results of the multivariate logistic
regression analysis. As presented, age remained independ-
ently and negatively associated with past year quasi-legal
Table 1 Drug use patterns among HIV-positive male and female patients accessing HIV care in Japan (n = 963)
Characteristic Total n (%) Male Female p – value
918 (95.3%) 45 (4.7%)
Age (median, IQR) 42 (37–50) 42 (37–50) 41 (35–48) 0.4491
Calendar year of HIV diagnosis <0.0012
1984–2005 337 (35.0%) 309 (33.7%) 28 (62.2%)
2006–2009 302 (31.4%) 293 (31.9%) 9 (20.0%)
2010–2013 324 (33.6%) 316 (34.4%) 8 (17.8%)
Currently receiving ART 911 (94.6%) 870 (94.8%) 41 (91.1%) 0.2893
Annual income 0.0444
< 1 million Yena 272 (28.3%) 253 (27.5%) 19 (42.2%)
1–2.99 million Yena 242 (25.1%) 231 (25.2%) 11 (24.4%)
3–4.99 million Yena 243 (25.2%) 231 (25.2%) 12 (26.7%)
≥ 5 million Yena 206 (21.4%) 203 (22.1%) 3 (6.7%)
Quasi-legal psychoactive substance useb
Ever 510 (53.0%) 508 (55.3%) 2 (4.4%)
In the previous year 117 (12.2%) 117 (12.8%) 0 (0.0%)
Tryptamine-type derivatives (i.e., 5-MeO-DPT or Foxy) use
Ever 255 (26.5%) 255 (27.8%) 0 (0.0%)
In the previous year 4 (0.4%) 4 (0.4%) 0 (0.0%)
Cannabis use
Ever 91 (9.5%) 88 (9.6%) 3 (6.7%)
In the previous year 4 (0.4%) 4 (0.4%) 0 (0.0%)
Methamphetamine/amphetamine use
Ever 110 (11.4%) 109 (11.9%) 1 (2.2%)
In the previous year 23 (2.4%) 23 (2.5%) 0 (0.0%)
MDMA use
Ever 58 (6.0%) 58 (6.3%) 0 (0.0%)
In the previous year 4 (0.4%) 4 (0.4%) 0 (0.0%)
Heroin use
Ever 5 (0.5%) 5 (0.5%) 0 (0.0%)
In the previous year 0 (0.0%) 0 (0.0%) 0 (0.0%)
Cocaine use
Ever 22 (2.3%) 22 (2.4%) 0 (0.0%)
In the previous year 1 (0.1%) 1 (0.1%) 0 (0.0%)
Use of any drugs listed above
Ever 522 (54.2%) 517 (56.3%) 5 (11.1%)
In the previous year 127 (13.2%) 127 (13.8%) 0 (0.0%)
IQR interquartile range
1P-value was derived from the Wilcoxon Rank Sum Test
2Chi-square value = 15.475, df = 2
3Chi-square value = 1.125, df = 1
4Chi-square value = 8.098, df = 3
aUS$1.00 ≈ 100 Yen. “<1 million Yen” includes those without any income
bIncludes variations of synthetic cannabinoids, synthetic cathinones, phenethylamine and thiophene derivatives, and amyl nitrites (e.g., rush, poppers). At the time
of surveying, the possession or consumption of these substances was not prohibited
Hayashi et al. Substance Abuse Treatment, Prevention, and Policy  (2017) 12:11 Page 4 of 8
Table 2 Bivariate analyses of factors predicting past year quasi-legal psychoactive substance use among HIV-positive males accessing
HIV care in Japan (n = 895)
Characteristic Quasi-legal psychoactive substance use in the previous year Odds Ratio (95% CI) p - value
Yes 115 (12.9%) No 780 (87.1%)
Age
Median (IQR) 39 (33–44) 43 (37–52)
Per year older 0.95 (0.93–0.97) <0.001
Education
< Secondary education 1 (0.9%) 21 (2.7%) 0.32 (0.07–1.53) 0.153
≥ Secondary education 114 (99.1%) 759 (97.3%) ref
Currently living alone
Yes 61 (53.0%) 344 (44.1%) 1.43 (1.04–1.97) 0.028
No 54 (47.0%) 436 (55.9%) ref
Annual income
< 1 million Yena 28 (24.4%) 210 (26.9%) 0.76 (0.54–1.09) 0.444
1–2.99 million Yena 29 (25.2%) 196 (25.1%) 0.85 (0.52–1.39) 0.995
3–4.99 million Yena 28 (24.3%) 202 (25.9%) 0.80 (0.63–1.01) 0.518
≥ 5 million Yena 30 (26.1%) 171 (22.1%) ref
ART use
Currently on ART 106 (92.2%) 741 (95.0%) 0.62 (0.29–1.31) 0.210
Never on ART 9 (7.8%) 39 (5.0%) ref
Ever had AIDS
Yes 32 (27.8%) 236 (30.3%) 0.89 (0.55–1.43) 0.625
No 83 (72.2%) 544 (69.7%) ref
Perceived route of HIV exposure
Male-to-male sexual behaviour 111 (96.5%) 647 (82.9%) 5.70 (3.29–9.88) <0.001
Other 4 (3.5%) 133 (17.1%) ref
Engagement in HIV-related peer support groups in the previous year
Yes 9 (7.8%) 46 (5.9%) 1.36 (0.67–2.72) 0.394
No 106 (92.2%) 734 (94.1%) ref
Kessler psychological distress scale (K6)
Score of≥ 13 13 (11.3%) 99 (12.7%) 0.88 (0.48–1.61) 0.672
Score of < 13 102 (88.7%) 681 (87.3%) ref
Ever used tryptamine-type derivatives (5-MeO-DPT or Foxy)
Yes 65 (56.5%) 187 (24.0%) 4.12 (2.90–5.86) <0.001
No 50 (43.5%) 593 (76.0%) ref
Ever used cannabis
Yes 25 (21.7%) 62 (8.0%) 3.22 (1.79–5.78) <0.001
No 90 (78.3%) 718 (92.0%) ref
Ever used methamphetamine/amphetamine
Yes 41 (35.7%) 68 (8.7%) 5.80 (3.79–8.88) <0.001
No 74 (64.3%) 712 (91.3%) ref
Ever used MDMA
Yes 19 (16.5%) 39 (5.0%) 3.76 (2.41–5.87) <0.001
No 96 (83.5%) 741 (95.0%) ref
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psychoactive substance use. Factors that remained inde-
pendently and positively associated with past year quasi-
legal psychoactive substance use included: currently living
alone; male-to-male sexual behaviour as a perceived route
of HIV exposure; ever used 5-MeO-DPT/Foxy; and ever
used methamphetamine/amphetamine.
In the sub-analysis, among the 115 male participants
who used quasi-legal psychoactive substances in the pre-
vious year, 38 (33.0%) reported having never used other
illicit drugs. Sixty-nine (60.0%) individuals reported hav-
ing used drugs for sexual activities in the previous year.
Discussion
In our sample of PLHIV in Japan, illicit drug use was
much more common among males than females. The
most commonly used drugs among men were quasi-
legal psychoactive substances. Over half of male partici-
pants reported having ever used quasi-legal psychoactive
substances, and approximately 12% reported having used
these substances in the previous year. The majority
(97%) of those who used quasi-legal psychoactive sub-
stances in the previous year were presumably MSM. Ap-
proximately one-third of them had no history of using
other illicit drugs. In the multivariate analysis, the life-
time use of 5-MeO-DPT/Foxy or methamphetamine/
amphetamine, younger age, living alone, and male-to-
male sexual behaviour as a perceived route of HIV
exposure were independently and positively associated
with recent quasi-legal psychoactive substance use
among male PLHIV.
We found that male PLHIV who had ever used 5-MeO-
DPT/Foxy were more likely to have used quasi-legal psy-
choactive substances in the previous year. While the
cross-sectional nature of the study limits the assessment
of temporal relationships, available data and literature sug-
gest possible shifts in the patterns of drug use in this
setting, from the use of fully banned to yet-to-be-fully-
prohibited substances. As presented in Table 1, in our
sample, 5-MeO-DPT/Foxy were second-ranked among
the drugs that have ever been used in the lifetime (28%).
However, past year use substantially dropped to <0.5%.
Given that these tryptamine-type derivatives became fully
prohibited under the Narcotics and Psychotropics Control
Law in 2005, our findings suggest that “substance dis-
placement” might have occurred in this setting [18]
whereby those who had used these illegal stimulants may
Table 2 Bivariate analyses of factors predicting past year quasi-legal psychoactive substance use among HIV-positive males accessing
HIV care in Japan (n = 895) (Continued)
Ever used heroin or cocaine
Yes 8 (7.0%) 15 (1.9%) 3.81 (1.62–9.01) 0.002
No 107 (93.0%) 765 (98.1%) ref
IQR: interquartile range. ART: antiretroviral therapy
aUS$1.00 ≈ 100 Yen. “<1 million Yen” includes those without any income
Table 3 Multivariate logistic regression analysis of factors predicting past year quasi-legal psychoactive substance use among
HIV-positive males accessing HIV care in Japan (n = 895)
Variable Adjusted Odds Ratio 95% Confidence Interval p - value
Age
(per year older) 0.96 (0.93–0.99) 0.004
Living alone
(yes vs. no) 1.66 (1.10–2.49) 0.015
Perceived route of HIV exposure
(male-to-male sexual behaviour vs. other) 2.56 (1.48–4.43) <0.001
Ever used tryptamine-type derivatives (5-MeO-DPT or Foxy)
(yes vs. no) 2.42 (1.36–4.28) 0.003
Ever used cannabis
(yes vs. no) 1.04 (0.51–2.12) 0.912
Ever used methamphetamine/amphetamine
(yes vs. no) 3.59 (2.13–6.04) <0.001
Ever used MDMA
(yes vs. no) 0.90 (0.54–1.48) 0.667
Ever used heroin or cocaine
(yes vs. no) 1.04 (0.56–1.96) 0.895
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have shifted to other quasi-legal psychoactive substances
with similar psychoactive effects as these psychoactive
substances became easily available. This is also congruent
with previous forensic laboratory reports suggesting that
stricter controls of certain substances have met with the
emergence of new analogues of controlled substances in
Japan [16].
Likewise, the independent association between lifetime
use of methamphetamine/amphetamine and recent use of
quasi-legal psychoactive substances could also be inter-
preted as switching from the former to the latter. How-
ever, a recent qualitative study reported that quasi-legal
psychoactive substance use might subsequently lead to the
use of methamphetamine/amphetamine among some
PLHIV in Japan [19]. In light of this previous study find-
ing, the observed association may also suggest that some
of those who used quasi-legal psychoactive substances in
the previous year subsequently used methamphetamine/
amphetamine. Future research should determine the
potential role of quasi-legal psychoactive substance use in
the initiation of methamphetamine/amphetamine use in
this setting.
We also found that those who were younger and those
who were likely MSM were more likely to report recent
use of quasi-legal psychoactive substances. This is con-
sistent with a previous study conducted in Tokyo [12].
According to a recent qualitative investigation of pat-
terns of illicit drug use among HIV-positive MSM in
Japan, illicit drugs (including quasi-legal psychoactive
substances) were used for several purposes in this popu-
lation, including as a strategy to cope with depression
and sexual minority stress, and as a sexual stimulant
[20]. Regardless of the purposes, illicit drug use often
resulted in increasing sexual HIV risk behaviour [20].
Consistent with these qualitative research findings, in
our study, two-thirds of the past year quasi-legal psycho-
active substance users reported having used drugs for
sexual purposes. Previous literature also indicated high
rates of sexual stimulant use among HIV-positive MSM
in other countries [21]. Ongoing quasi-legal psychoactive
substance use and the potentially associated risky sexual
behaviour among HIV-positive MSM are concerning.
They warrant greater efforts to address factors that lead
to illicit drug use and to reduce drug-related harms in
this setting.
Internationally, identifying effective regulations of
new psychoactive substances is a major topic of de-
bate [22, 23]. In April 2014, the Japanese government
penalized the personal possession and consumption of
all Designated Substances [24]. This legislation change
in Japan, which outright banned more than 1,300
Designated Substances [24], could be viewed as a bold
attempt to contain the illicit psychoactive substance
market through law enforcement. Some commentators
raised a concern regarding the overreliance on such
law enforcement-based approaches [25]. They claimed
that as new psychoactive substances are moving tar-
gets, such approaches may potentially increase the
drug-related harm among those who continue to use
those controlled substances [25]. Our findings sug-
gesting the possible shift from the use of banned to
unregulated substances reinforce the concern. Given
that new unregulated substances may pose increased
or different kinds of harm, the findings indicate a
need to address various social and structural factors
that predispose vulnerable populations to illicit drug
use and the associated harm.
Our study has several limitations. First, as the study
sample was not randomly selected, our findings may not
be generalizable to PLHIV in Japan or elsewhere. Second,
the self-reported data may be affected by reporting biases,
including recall bias and socially desirable responding.
However, we note that the anonymous nature of the ques-
tionnaire may have helped reduce some of the biases.
Third, as with all observational studies, the associations
between the explanatory variables and outcome assessed
may be under the influence of unmeasured confound-
ing factors. However, we sought to address this bias
with multivariate adjustment of the key demographic
and behavioural predictors of quasi-legal psychoactive
substance use.
Conclusion
In sum, illicit drug use was much more common among
male patients in HIV care in Japan, compared to their fe-
male counterparts. Among male participants, quasi-legal
psychoactive substances were the most commonly used
drugs. We also found a substantial decline in recent use of
5-MeO-DPT/Foxy. Individuals who had ever used these
tryptamine derivatives or methamphetamine/amphetamine
were more likely to report recent quasi-legal psychoactive
substance use. These findings suggest a potential shift in
drug use patterns from regulated to unregulated substances
among this population. Given that a new regulation insti-
tuted in April 2014 fully banned presumably most of the
quasi-legal psychoactive substances considered in this
study, further research is warranted to examine changing
drug patterns and implications for HIV care in this setting.
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